Ligand Pharmaceuticals Inc (LGND) stock
LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30433% above fair value
$298.71+4.90 (+1.67%)
Close on Nov 18, 2026Market cap $5.98BP/E 130.4Yield –
Ligand Pharmaceuticals pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Ligand Pharmaceuticals's pe ratio was 33.7× on Nov 11, 2026, against 105.3× a year earlier. Over the last 5 years it ranged from 2.3× to 105.3×, with a median of 38.7×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 33.7× | −64.3 |
| 2025 | Dec 31, 2025 | 98.0× | +55.3 |
| 2024 | Dec 31, 2024 | 42.7× | −48.9 |
| 2023 | Dec 29, 2023 | 91.6× | +23.9 |
| 2022 | Jul 29, 2022 | 67.7× | +29.0 |
| 2021 | Dec 31, 2021 | 38.7× | +35.6 |
| 2020 | Apr 30, 2020 | 3.1× | −0.7 |
| 2019 | Dec 31, 2019 | 3.8× | −20.5 |
| 2018 | Dec 31, 2018 | 24.2× | +6.6 |
| 2017 | Dec 29, 2017 | 17.6× | −281.2 |
| 2016 | Dec 30, 2016 | 298.9× | +288.8 |
| 2015 | Dec 31, 2015 | 10.1× | −156.2 |
| 2014 | Dec 31, 2014 | 166.3× | +63.1 |
| 2013 | Dec 31, 2013 | 103.1× | −193.1 |
| 2012 | Dec 31, 2012 | 296.3× | +272.1 |
| 2011 | Dec 30, 2011 | 24.2× | – |
See a number that looks wrong?